Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Impact of Coverage of GLP-1 Drugs for Obesity on Medicare Expenditure s Source: JAMA Health Forum Hwang, April 25, 2025 Researchers in JAMA Health Forum used a microsimulation model to assess the likely financial results of Medicare covering GLP-1 drugs for obesity
Since liraglutide is not metabolized or eliminated by the kidneys or liver, its pharmacokinetics are not significantly affected by renal or hepatic dysfunction, providing a potential treatment advantage in patients with type 2 diabetes and concomitant kidney/liver disease [59]
Patients taking statins who develop new muscle symptoms while on GLP-1 therapy should contact their prescriber promptly, as this combination may increase the risk of muscle-related adverse effects in some individuals
As fat tissue decreases, the support structures around the bladder and urethra adjust, and this transition period can temporarily weaken continence control
US$ 22.78
US$ 26.49
US$ 29.57
US$ 25.98
